Inhibrx Biosciences (INBX) Operating Expenses (2023 - 2026)

Inhibrx Biosciences (INBX) has reported Operating Expenses for 3 consecutive years, with $30.9 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Operating Expenses fell 38.19% year-over-year to $30.9 million; the TTM figure through Dec 2025 stood at $136.3 million (down 58.89% YoY), while the FY2025 annual figure was $136.3 million, down 58.89% from the prior year.
• Operating Expenses retreated to $30.9 million in Q4 2025 per INBX's latest filing, from $33.8 million in the prior quarter.
• Across five years, Operating Expenses topped out at $161.0 million in Q2 2024 and bottomed at $28.7 million in Q2 2025.
• Historically, Operating Expenses has averaged $58.7 million across 3 years, with a median of $45.9 million in 2023.
• Annual changes were most pronounced in 2024 — Operating Expenses soared 289.18% — and 2025, when it tumbled 82.18%.
• Inhibrx Biosciences' Operating Expenses stood at $89.9 million in 2023, then slumped by 44.37% to $50.0 million in 2024, then slumped by 38.19% to $30.9 million in 2025.
• Business Quant data shows INBX's Operating Expenses at $30.9 million in Q4 2025, $33.8 million in Q3 2025, and $28.7 million in Q2 2025.